Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
Although breast cancer has a good prognosis compared with various cancers, metastatic breast cancer has an aggressive disease course and remains incurable. Therefore, treatment of early breast cancer to prevent recurrence and metastasis is crucial. Recently, the development of anti-cancer drugs, suc...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977622001801 |
| _version_ | 1797979772405415936 |
|---|---|
| author | Jae Ho Jeong Sung-Bae Kim |
| author_facet | Jae Ho Jeong Sung-Bae Kim |
| author_sort | Jae Ho Jeong |
| collection | DOAJ |
| description | Although breast cancer has a good prognosis compared with various cancers, metastatic breast cancer has an aggressive disease course and remains incurable. Therefore, treatment of early breast cancer to prevent recurrence and metastasis is crucial. Recently, the development of anti-cancer drugs, such as targeted agents and immuno-oncology, has been accelerating. Antibody-drug conjugates (ADCs) are also building a new paradigm. Particularly, ADCs targeting Trop-2 were approved for their efficacy in metastatic triple-negative breast cancer patients who received ≥2 prior systemic therapies and showed significant results in heavily pretreated hormone receptor-positive/HER2-negative breast cancer. In this brief review, we provide an overview of ongoing clinical trials of ADCs targeting Trop-2 in early breast cancer, specifically sacituzumab govitecan. |
| first_indexed | 2024-04-11T05:44:00Z |
| format | Article |
| id | doaj.art-e8736a0498f74f4da019f076998253f4 |
| institution | Directory Open Access Journal |
| issn | 1532-3080 |
| language | English |
| last_indexed | 2024-04-11T05:44:00Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Breast |
| spelling | doaj.art-e8736a0498f74f4da019f076998253f42022-12-22T04:42:19ZengElsevierBreast1532-30802022-12-0166199203Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapyJae Ho Jeong0Sung-Bae Kim1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaCorresponding author. Ph.D. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaAlthough breast cancer has a good prognosis compared with various cancers, metastatic breast cancer has an aggressive disease course and remains incurable. Therefore, treatment of early breast cancer to prevent recurrence and metastasis is crucial. Recently, the development of anti-cancer drugs, such as targeted agents and immuno-oncology, has been accelerating. Antibody-drug conjugates (ADCs) are also building a new paradigm. Particularly, ADCs targeting Trop-2 were approved for their efficacy in metastatic triple-negative breast cancer patients who received ≥2 prior systemic therapies and showed significant results in heavily pretreated hormone receptor-positive/HER2-negative breast cancer. In this brief review, we provide an overview of ongoing clinical trials of ADCs targeting Trop-2 in early breast cancer, specifically sacituzumab govitecan.http://www.sciencedirect.com/science/article/pii/S0960977622001801Early breast cancerAntibody-drug conjugatesTrop-2Sacituzumab govitecanNeoadjuvantAdjuvant |
| spellingShingle | Jae Ho Jeong Sung-Bae Kim Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy Breast Early breast cancer Antibody-drug conjugates Trop-2 Sacituzumab govitecan Neoadjuvant Adjuvant |
| title | Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy |
| title_full | Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy |
| title_fullStr | Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy |
| title_full_unstemmed | Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy |
| title_short | Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy |
| title_sort | antibody drug conjugates targeting trop 2 clinical developments in early breast cancer therapy |
| topic | Early breast cancer Antibody-drug conjugates Trop-2 Sacituzumab govitecan Neoadjuvant Adjuvant |
| url | http://www.sciencedirect.com/science/article/pii/S0960977622001801 |
| work_keys_str_mv | AT jaehojeong antibodydrugconjugatestargetingtrop2clinicaldevelopmentsinearlybreastcancertherapy AT sungbaekim antibodydrugconjugatestargetingtrop2clinicaldevelopmentsinearlybreastcancertherapy |